What's in Crucell Holland BV's pipeline?

Crucell Holland BV has 22 drugs in our index: 4 marketed, 0 filed, 8 in Phase 3, 4 in Phase 2, 6 in Phase 1.

Which companies overlap with Crucell Holland BV's portfolio?

Top competitors by shared drug class: Vaxxinity, Inc., Bharat Biotech International Limited, GlaxoSmithKline, Merck Sharp & Dohme LLC, CanSino Biologics Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/crucell-holland-bv.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Crucell Holland BV — Portfolio Competitive Intelligence Brief

Crucell Holland BV pipeline: 4 marketed, 0 filed, 8 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 8 Phase 3 4 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Inflexal V	Inflexal V	marketed
Engerix B	Engerix B	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)	Immunology
HAVpur Junior	HAVpur Junior	marketed	Inactivated viral vaccine	Hepatitis A virus (HAV)	Immunology / Infectious Disease
Quinvaxem/Tritanrix	Quinvaxem/Tritanrix	marketed	Pentavalent vaccine		Immunology
Ad26.ZEBOV-Batch #3	Ad26.ZEBOV-Batch #3	phase 3	Viral vector vaccine	Ebola virus glycoprotein (EBOV GP)	Immunology / Infectious Disease
Ad26.ZEBOV-Batch #2	Ad26.ZEBOV-Batch #2	phase 3	Viral vector vaccine	Ebola virus glycoprotein (GP)	Immunology / Infectious Disease
Ad26.ZEBOV-Batch #1	Ad26.ZEBOV-Batch #1	phase 3	Viral vector vaccine	Ebola virus glycoprotein (GP)	Immunology / Infectious Disease
Epaxal	Epaxal	phase 3			Other
HepavaxGene (thiomersal free)	HepavaxGene (thiomersal free)	phase 3	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)	Immunology / Infectious Disease
Quinvaxem in single dose vials	Quinvaxem in single dose vials	phase 3	Pentavalent conjugate vaccine		Immunology / Infectious Disease
Havrix 720	Havrix 720	phase 3	Inactivated viral vaccine	Hepatitis A virus antigen	Immunology / Infectious Disease
Quinvaxem in Uniject	Quinvaxem in Uniject	phase 3	Pentavalent conjugate vaccine		Immunology

Therapeutic area mix

Immunology / Infectious Disease · 7
Immunology · 3
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Vaxxinity, Inc. · 2 shared drug classes
Bharat Biotech International Limited · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
CanSino Biologics Inc. · 1 shared drug class
Cellid Co., Ltd. · 1 shared drug class
Aeras · 1 shared drug class
Boryung Pharmaceutical Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Crucell Holland BV:

Cite this brief

Drug Landscape (2026). Crucell Holland BV — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/crucell-holland-bv. Accessed 2026-05-16.